Is Novo Nordisk shares a candidate to buy? Analysis and opinions from financial experts.

Is Novo Nordisk shares a candidate to buy? Analysis and opinions from financial experts.

According to a report by www.wallstreet-online.de Analysts have different opinions regarding Novo Nordisk shares. While many investors are optimistic about the boom in weight-loss drugs this year, analysts at Jefferies are raising concerns about the Danish drugmaker's future performance.

The launch of rival Eli Lilly's anti-obesity drug, as well as the risk of disappointment from Wegovy's slower-than-expected supply ramp-up, could influence sentiment next year. Eli Lilly's weight loss drug, Zepbound, received US Food and Drug Administration (FDA) approval in early November.

These uncertainties raise questions about what impact this could have on the market, consumers and the pharmaceutical industry as a whole. If the mood actually changes and the introduction of competing products affects profit expectations, investor uncertainty and possibly a decline in the share price can be expected. Confidence in the company's products could be weakened and the growth of the pharmaceutical market as a whole could be affected.

It is therefore important to keep an eye on developments at Novo Nordisk and in the pharmaceutical sector and make appropriate investment decisions with caution.